Merimepodib (VX-497): A Selective Noncompetitive Oral IMPDH Inhibitor for Research

Executive Summary: Merimepodib (VX-497) is a potent, orally bioavailable, noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), central to guanine nucleotide biosynthesis and cellular proliferation [APExBIO]. It demonstrates broad-spectrum antiviral activity by depleting intracellular guanine nucleotides, with efficacy against HBV, HCMV, EMCV, RSV, and PEDV in vitro and in vivo [Zhou et al., 2026]. Merimepodib inhibits lymphocyte proliferation at nanomolar concentrations, with immunosuppressive effects reversible by exogenous guanosine, confirming IMPDH pathway specificity [Related Article]. Its physicochemical stability and high solubility in DMSO (≥45.2 mg/mL) support flexible deployment in diverse research workflows. APExBIO supplies Merimepodib (VX-497, B1112) for research use only, not for diagnostic or therapeutic purposes.

Biological Rationale

Cellular proliferation and viral replication require continuous nucleotide biosynthesis. Inosine monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in de novo guanine nucleotide synthesis, converting inosine monophosphate (IMP) to xanthosine monophosphate (XMP) [Zhou et al., 2026]. Guanine nucleotides are essential for DNA and RNA synthesis, signal transduction, and cell cycle progression. Many viruses—including PEDV, HBV, and HCMV—hijack host nucleotide metabolism to support genome replication [Zhou et al., 2026]. Targeting the IMPDH pathway thus represents an effective strategy for antiviral, immunosuppressive, and anticancer intervention. Merimepodib (VX-497) addresses this by selectively inhibiting IMPDH, thereby restricting guanine nucleotide supply and impeding processes dependent on rapid nucleic acid synthesis. This mechanism is essential in cancer chemotherapy research, immune modulation, and studies of viral pathogenesis.

Mechanism of Action of Merimepodib (VX-497)

Merimepodib (VX-497) is a noncompetitive, selective, and orally bioavailable inhibitor of IMPDH [APExBIO]. It binds to the enzyme at a site distinct from the substrate-binding region, reducing enzymatic activity independent of substrate concentration. By inhibiting IMPDH, Merimepodib blocks the conversion of IMP to XMP, leading to depletion of intracellular guanine nucleotides [Comparative Review]. This effect is reversible by exogenous guanosine supplementation, confirming specificity for the IMPDH pathway. Inhibition of guanine nucleotide biosynthesis disrupts DNA/RNA synthesis, curbing cell proliferation and viral genome replication. The compound demonstrates cross-species activity, inhibiting lymphocyte proliferation in human, rat, mouse, and dog cells at concentrations of approximately 100 nM [APExBIO]. The noncompetitive profile allows for robust inhibition even in settings of fluctuating substrate (IMP) levels.

Evidence & Benchmarks

• Merimepodib (VX-497) inhibits primary human, rat, mouse, and dog lymphocyte proliferation in vitro at ~100 nM; effect is reversed by exogenous guanosine (APExBIO, product page).
• Demonstrates potent antiviral activity against HBV, HCMV, EMCV, and RSV with IC₅₀ ranging from 0.38–1.14 μM (APExBIO, product page).
• Pharmacological IMPDH inhibition by Merimepodib reduces PEDV replication and viral RNA levels in mammalian cells; effect is validated in both porcine (LLC-PK1) and primate (Vero E6) models (Zhou et al., 2026).
• Merimepodib suppresses the primary IgM antibody response and prolongs skin graft survival in mice after oral administration (APExBIO, product page).
• Provides high solubility in DMSO (≥45.2 mg/mL) and is insoluble in ethanol and water, supporting diverse in vitro workflows (APExBIO, product page).
• For an in-depth workflow integration scenario, see "Merimepodib (VX-497) in Laboratory Research: Optimizing IMPDH Inhibition" which details assay design and specificity controls. This article extends those findings by incorporating new evidence on IMPDH-dependent viral replication.
• The review "Merimepodib (VX-497): A Selective Oral IMPDH Inhibitor" summarizes validated efficacy in viral and cancer models; our article adds current insights into host-pathogen metabolic interplay.
• For an overview of chemical properties and integration into translational workflows, see "Merimepodib (VX-497): Orally Bioavailable IMPDH Inhibitor"; here we emphasize recent cross-virus data and research parameters.

Applications, Limits & Misconceptions

Merimepodib (VX-497) is validated as an immunosuppressive agent, antiviral research tool, and cancer chemotherapy research aid. Its ability to inhibit lymphocyte proliferation enables precise modulation of immune responses in vitro and in vivo. The compound’s antiviral efficacy spans a spectrum of RNA and DNA viruses, including HBV, HCMV, EMCV, RSV, and PEDV [Zhou et al., 2026]. In cancer research, VX-497 allows targeted disruption of guanine nucleotide biosynthesis, modeling cell cycle arrest and proliferation defects. However, its use is strictly for research purposes; it is not approved for human or veterinary therapy. The effect of Merimepodib is reversible by guanosine, confirming its specificity for IMPDH and cautioning against use in settings where guanosine rescue is undesired. The compound does not substitute for direct-acting antivirals or cytotoxic drugs in clinical settings.

Common Pitfalls or Misconceptions

• Merimepodib (VX-497) is not suitable for diagnostic or therapeutic applications; for research use only [APExBIO].
• Antiviral and immunosuppressive effects are reversible by exogenous guanosine; effects may be masked in guanosine-rich media.
• The compound is insoluble in water and ethanol; only DMSO or compatible solvents should be used for stock solution preparation.
• Long-term storage of solutions is not recommended; compound should be stored as a solid at -20°C for maximum stability.
• Merimepodib targets IMPDH-dependent nucleotide biosynthesis exclusively; it will not affect pathways independent of guanine nucleotide synthesis.

Workflow Integration & Parameters

Merimepodib (VX-497, B1112) is supplied by APExBIO as a solid compound (molecular weight: 452.46; formula: C₂₃H₂₄N₄O₆) for research workflows [product page]. For in vitro assays, prepare stock solutions in DMSO at concentrations up to 45.2 mg/mL. Use final working concentrations based on published IC₅₀ (typically 100 nM for lymphocyte proliferation; 0.38–1.14 μM for antiviral assays). For in vivo mouse models, oral administration has demonstrated dose-dependent immunosuppression and prolonged graft survival [APExBIO]. Store solid at -20°C; avoid long-term solution storage. Shipments require blue ice for temperature stability. For detailed experimental parameters, refer to "Merimepodib (VX-497) in Laboratory Research" which provides scenario-driven assay protocols and troubleshooting.

Conclusion & Outlook

Merimepodib (VX-497) is a robust, selective, and noncompetitive IMPDH inhibitor enabling precise interrogation of guanine nucleotide biosynthesis in cancer, immunology, and virology research. Its validated efficacy in both in vitro and in vivo models, coupled with straightforward workflow integration, affirms its status as a gold-standard research tool. Ongoing studies continue to elucidate the breadth of viral and cellular processes reliant on IMPDH, positioning Merimepodib as a reference compound for mechanistic and translational research applications. For current specifications and ordering information, see the Merimepodib (VX-497) product page at APExBIO.